pa旗舰厅
中
繁
EN
pa旗舰厅:For Patients
pa旗舰厅:Investors
Careers
Contact
Home
About Us
pa旗舰厅:Our Story
pa旗舰厅:Leadership
pa旗舰厅:Board of Directors
pa旗舰厅:Jacobio people stories
pa旗舰厅:Platform & Pipeline
Platform
Pipeline
pa旗舰厅:Publications
pa旗舰厅:Partnership
News
pa旗舰厅:Company News
pa旗舰厅:Media Report
For patients
5
Clinical Trials Found
Drug:
JAB-21822 Monotherapy
Indication:
NSCLC, PDAC, CRC, Other advanced solid tumors
Region:
US, Europe
Link:
JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation/JAB-21822-1001
Drug:
JAB-21822 in combination with Cetuximab
Indication:
CRC
Region:
US, Europe
Link:
JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation/JAB-21822-1001
Drug:
JAB-8263 Monotherapy
Indication:
BRD-NUT, Prostate cancer, Other advanced solid tumors
Region:
US
Link:
JAB-8263 monotherapy in adult participants with advanced solid tumors/JAB-8263-1001
Drug:
JAB-BX102 Monotherapy
Indication:
Thyroid cancer, ACC, Other advanced solid tumors
Region:
China, US
Link:
JAB-BX102 monotherapy in adult participants with advanced solid tumors/JAB-BX102-1001
Drug:
JAB-2485 Monotherapy
Indication:
TNBC, SCLC, ER+Breast Cancer, Other advanced solid tumors
Region:
China, US
Link:
JAB-2485 monotherapy in adult participants with advanced solid tumors/JAB-2485-1001